Checkmate Pharmaceuticals, Inc. (CMPI) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021

Checkmate Pharmaceuticals, Inc.

CIK: 1651431 Ticker: CMPI
Cover Page - USD ($)
12 Months Ended
Dec. 31, 2021
Mar. 29, 2022
Jun. 30, 2021
Document Information [Line Items]   
Document Type10-K  
Amendment Flagfalse  
Document Period End DateDec. 31, 2021  
Document Fiscal Year Focus2021  
Document Fiscal Period FocusFY  
Document Annual Reporttrue  
Document Transition Reportfalse  
Entity Interactive Data CurrentYes  
Entity Registrant NameCheckmate Pharmaceuticals, Inc.  
Entity Central Index Key0001651431  
Current Fiscal Year End Date--12-31  
Entity Current Reporting StatusYes  
Entity Well-known Seasoned IssuerNo  
Entity Voluntary FilersNo  
Entity Shell Companyfalse  
Entity Filer CategoryNon-accelerated Filer  
Entity Small Businesstrue  
Entity Emerging Growth Companytrue  
Entity Ex Transition Periodfalse  
Entity Incorporation, State or Country CodeDE  
Entity Address, State or ProvinceMA  
Title of 12(b) SecurityCommon Stock  
Trading SymbolCMPI  
Security Exchange NameNASDAQ  
Entity Public Float  $ 124,028,535
Entity Common Stock, Shares Outstanding 21,630,627 
ICFR Auditor Attestation Flagfalse  
Entity File Number001-39425  
Entity Address, Address Line One245 Main Street  
Entity Address, Address Line Two2nd Floor  
Entity Address, City or TownCambridge  
Entity Address, Postal Zip Code02142  
Entity Tax Identification Number36-4813934  
City Area Code617  
Local Phone Number682-3625  
Auditor NameKPMG LLP  
Auditor Firm ID185  
Auditor LocationBoston, Massachusetts  

View differences made from one year to another to evaluate Checkmate Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Checkmate Pharmaceuticals, Inc..


Assess how Checkmate Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Checkmate Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools


Learn More
Bullish Bearish Neutral
Filter Sentiment:
Filter Category:
Filter Subcategory:
Cash Flow
Inside Checkmate Pharmaceuticals, Inc.'s 10-K Annual Report:

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit)
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Common Stock
Convertible Notes
Convertible Notes - Additional Information (Detail)
Defined Contribution Plan
Defined Contribution Plan - Additional Information (Detail)
Fair Value Measurement
Fair Value Measurement (Tables)
Fair Value Measurement - Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis (Detail)
Going Concern
Going Concern - Additional Information (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Components Of Company Deferred Tax Assets (Detail)
Income Taxes - Schedule Of Reconciliation Of U.S. Federal Statutory Income Tax Rate And Effective Income Tax Rate (Detail)
Income Taxes - Summary Of Unrecognized Benefits (Detail)
Investments (Tables)
Investments - Summary Of Amortized Cost And Estimated Fair Value Company's Available For Sale Investments (Detail)
Nature Of Business
Nature Of Business - Additional Information (Detail)
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock - Additional Information (Detail)
Stock Based Compensation - Schedule Of Fair Value Of Stock Option Awards On The Grant Date Using The Black-Scholes Option Valuation Model (Detail)
Stock Based Compensation - Summary The Activity Under The Company's Stock Option Plan (Detail)
Stock-Based Compensation
Stock-Based Compensation (Tables)
Stock-Based Compensation - Additional Information (Detail)
Stock-Based Compensation - Summary Of Total Stock-Based Compensation Expense (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies -Additional Information (Detail)

Material Contracts, Statements, Certifications & more

Checkmate Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CMPI
CIK: 1651431
Form Type: 10-K Annual Report
Accession Number: 0001193125-22-088386
Submitted to the SEC: Tue Mar 29 2022 7:04:18 PM EST
Accepted by the SEC: Wed Mar 30 2022
Period: Friday, December 31, 2021
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: